ArticleEndocrine, metabolic & immune disorders drug targets2026
Immune Cell-specific Genetic Regulation in Graves' Disease: An Integrative Mendelian Randomization Study.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGraves' disease (GD) is an autoimmune form of hyperthyroidism. We integrated GD GWAS summary statistics with immune-cell eQTLs to prioritize cell-type-specific genes with potential relevance to GD susceptibility.
methodsWe analyzed European-ancestry GD GWAS summary statistics from FinnGen Release 12 together with cis-eQTLs from 14 peripheral immune-cell subsets in the OneK1K single-cell resource (982 donors). We prioritized associations using SMR and HEIDI filtering, and Bayesian colocalization (COLOC) analysis was then performed to assess whether eQTL and GD association signals were likely to share a causal variant. Differential expression analysis using GSE71956 was used as additional transcriptomic support.
resultsAfter harmonization, 5,048 instrument-gene pairs were retained. MR identified 173 nonredundant genes (FDR < 0.05); SMR plus HEIDI retained 159 genes across the 14 immune subsets. COLOC highlighted 33 high-confidence colocalized signals (PPH4 > 0.90), including ARID5B in CD4 DISCUSSION: Concordant evidence across methods supports these signals, but residual pleiotropy and the European-only design remain important caveats. Differences from prior reports may reflect cell-type context and disease stage.
conclusionImmune subset-resolved eQTL-GWAS integration points to specific genes and pathways that may contribute to GD susceptibility and helps narrow candidates for follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.